Gilead Sciences | GILD - Gross Profit On Sales

Stock Price
140.51
Daily Change
-0.78 -0.55%
Monthly
-7.19%
Yearly
32.72%
Q1 Forecast
140.61

Gilead Sciences reported $6.31B in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
ALKERMES USD 338.34M 72.51M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Coherus Biosciences USD 8.7M 853K Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Gilead Sciences USD 6.31B 106M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Incyte USD 1.39B 118.68M Dec/2025
J&J USD 16.6B 118M Dec/2025
Merck USD 13.42B 431M Sep/2025
Moderna USD 226M 583M Dec/2025
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Novartis USD 10.82B 695M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
United Therapeutics USD 315.5M 286.6M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025